Trial · NCT07423078
Window of Opportunity in Preserving Laryngeal Function Trial
NCT07423078, Phase 2, Recruiting, Matthew Spector
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Window of Opportunity in Preserving Laryngeal Function Trial. Trials, record NCT07423078. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07423078
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Window of Opportunity in Preserving Laryngeal Function Trial
- NCT number
- NCT07423078
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 87 participants, estimated
- Lead sponsor
- Matthew Spector
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Interventions
- Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy
- First posted
- 2026-02-20
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1-Year Disease-free survival (DFS) | At 1 year | Proportion of patients who have not experienced disease recurrence/progression or death from any cause at 1 year from start of treatment. Radiologic (CT or MRI) imaging as well as direct visualization by laryngoscopy will be used to assess disease with recurrence requiring a biopsy to be considered positive. |
| Secondary | Overall Survival (OS) | Up to 5 years | Median time from initiation of study therapy to death from any cause. |
| Secondary | Larynx preservation rate | Up to 5 years | The proportion of responding patients (without disease recurrence/progression or death from any cause) who do not undergo laryngectomy during the study period. Radiologic (CT or MRI) imaging as well as direct visualization by laryngoscopy will be used to assess disease with recurrence requiring a biopsy to be considered positive. |
| Secondary | Prevalence of swallowing impairment | At baseline, at 3 weeks after completion of induction therapy, at 6 months into the treatment continuation period, and at 1 year into the treatment continuation period. Total timeframe of data collection up to 14.5 months from start of induction therapy. | The proportion of participants with swallowing impairment. Swallowing impairment may be evaluated by flexible endoscopic examination of swallowing (FEES), modified barium swallow (MBS), or another method at the discretion of the treating physician. The physician will indicate the presence or absence of impairment of the pharynx and/or larynx that effects swallowing at each stated timepoint. |
| Secondary | Neck Dissection Impairment Index (NDII) | At Baseline, at every (21 day) treatment cycle, up to 1-year ± 14 days | Patient Reported Outcome Measure (PROM) is a 10-item, self-report instrument. A 5-level Likert scale is used for responses ranging from 'not at all' = 10 to 'a lot' = 0 related to pain/discomfort and limitation of movement as a result of cancer treatment. The NDII scores range from 0 to 100, with higher scores indicating better shoulder functioning and quality of life (QOL). Factors such as age, weight, radiation treatment, and neck dissection type significantly affect the QOL score. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07423078
GET https://conductscience.org/api/trials/v1/NCT07423078/registered